沃特世公司 WAT

Udit Batra, President and Chief Executive Officer. Career Highlights: Merck KGaA - CEO of MilliporeSigma (life sciences business) (2014 - 2020), President and CEO, Consumer Health (2011 - 2014); Novartis International AG - Various leadership roles (2006 - 2011); Johnson & Johnson - Global Brand Director, Wound Care (2004 - 2005); McKinsey & Company - Senior Engagement Manager (2001 - 2004); Merck & Co., Inc. - Research Fellow (1996 - 2001). Education: BS, University of Delaware; PhD, Chemical Engineering, Princeton University.

Amol Chaubal, was appointed Chief Financial Officer of Waters Corporation on May 12, 2021. Previously, Mr. Chaubal was Chief Financial Officer of Quanterix Corporation, a life sciences company, where he served as Chief Financial Officer since April 2019. Before Quanterix, Mr. Chaubal served as Chief Financial Officer, Global Operations at Smith & Nephew, a global medical devices company, from October 2017 to April 2019. Prior to his time at Smith & Nephew, he served as Corporate Vice President and Head of Finance for the Clinical Research Services and Access business at Parexel from July 2015 to October 2017.

Jianqing Bennett, was appointed Senior Vice President of TA Instruments Division on May 1, 2021. Previously, Ms. Bennett served as Senior Vice President, High Growth Markets at Beckman Coulter Diagnostics from November 2017 to March 2021. Prior to that, from 2007-2017, she held various senior management positions at Carestream Health Inc, including serving as President, Medical Digital Solutions from August 2015 to November 2017.

Dr. Flemming Ornskov, Chairman of the Board. Career Highlights: Galderma - CEO and Chair (2019 - present); Shire plc - CEO and Board member (2013 - 2019); Bayer AG - Chief Marketing Officer and Global Head of Strategic Marketing for General & Specialty Medicine (2010 - 2012); Bausch & Lomb, Inc. - Global President, Pharmaceuticals and OTC (2008 - 2010); Merck & Co. Inc. and Novartis AG - Various roles of increasing responsibility. Other Public Company Boards: Galderma (SIX: GALD) (2019 - present). Former (past 5 Years): Centogene NV (NSDQ: CNTG) (2019-2023); Karo Pharma AB n/k/a Karo Healthcare AB (STO: KARO) (2019 - 2022, when taken private). Education: MD, University of Copenhagen Medical School; MPH, Harvard University School of Public Health; MBA, INSEAD

Ms. Linda Baddour, Independent Director. Career Highlights: PRA Health Sciences: EVP and CFO (2007 - 2018); Pharmaceutical Product Development, Inc: CFO and Accounting Officer (2002 - 2007), Chief Accounting Officer (1997 - 2007), Corporate Controller (1995 - 1997); Cooperative Bank for Savings Inc. - Controller (1980 - 1995). Other Public Company Boards: Cryoport, Inc. (NSDQ: CYRX) (2021 - present). Education: BA and MBA, University of North Carolina at Wilmington.

Mr. Daniel J. Brennan, Independent Director. Career Highlights: Boston Scientific Corporation: EVP and CFO (2014-present), SVP and Corporate Controller (2010 - 2013), various roles of increasing responsibility within finance function (1996 - 2009); Millipore Corporation - Roles of increasing responsibility in corporate finance function (1990 - 1996); Standex, Inc. - Corporate Auditor (1988 - 1989). other Public Company Boards: Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (2025 - present). Former (past 5 Years): Nuance Communications (NASDAQ: NUAN) (2018 - 2022). Education: BS and MBA, Babson College.

Mr. Richard H. Fearon, Independent Director. Career Highlights: Eaton Corporation - Vice Chairman, Chief Financial and Planning Officer (2009 - 2021), Chief Financial and Planning Officer (2002 - 2021); Avient Corporation - Non-Executive Chairman of the Board (2023 - present), Lead Director (2015 - 2023); Transamerica Corporation - SVP, Corporate Development and Strategic Planning (1997 - 2001), VP, Corporate Development (1995 - 1997); NatSteel Ltd: Vice Chairman, NatSteel Chemicals and General Manager, Corporate Development (1990 - 1995); Various positions at Booz Allen Hamilton, The Walt Disney Company, and The Boston Consulting Group. Other Public Company Boards: CRH plc (NYSE: CRH) (2020 - present); Crown Holdings, Inc. (NYSE: CCK) (2019 - present); Avient Corporation (NYSE: AVNT) (2003 - present). Former (past 5 Years): Eaton Corporation plc (NYSE: ETN) (2015 - 2021); Hennessy Capital Investment Corporation VI (NASDAQ: HCVIU) (2021 - 2023). Education: AB, Stanford University; JD and MBA, Harvard University.

Mr. Christopher A. Kuebler, Independent Director. Career Highlights: Covance Inc. and its predecessor companies - Chairman (2005), Chairman and CEO (1994 - 2004); Spent nearly 20 years in the pharmaceutical industry at Abbott Laboratories, Squibb, Inc., and the Monsanto Company. Education: BS, Biology, Florida State University.

Dr. Pearl S. Huang, PhD, Independent Director. Career Highlights: Dunad Therapeutics - President and CEO (2022 - present); Cygnal Therapeutics - CEO (2019 - 2022); Flagship Pioneering - Venture Partner (2019 - 2022); F. Hoffman La-Roche, Ltd. - SVP and Global Head, Therapeutic Modalities (2014 - 2018); GlaxoSmithKline plc - VP and Global Head of Discovery Academic Partnerships (DPAc) Alternative Discovery and Development, (2012 - 2014); Beigene LTD - Founder and CSO (2010 - 2012); Merck and Co. - VP, Oncology Integrator, Discovery and Early Development (2006 - 2010); Held roles of increasing responsibility at Merck & Co. Inc. and GlaxoSmithKline plc. Other Public Company Boards: BB Biotech AG (SIX: BION) (2022 - present). Education: BS, Biology, MIT; Ph.D., Molecular Biology, Princeton University.

Mr. Mark P. Vergnano, Independent Director. Career Highlights: The Chemours Company - Chairman (2021), President and CEO (2015 - 2021); DuPont - EVP (2009 - 2015), Group VP, Safety and Protection (2006 - 2009), VP, General Manager, Nonwovens and Building Innovations (2002 - 2006), other various roles (1980 - 2002). Other Public Company Boards: Johnson Controls International PLC (NYSE: JCI) (July 2016 - present). Former (past 5 Years): The Chemours Company (NYSE: CC) (2015 - 2022). Education: BS, University of Connecticut; MBA, Virginia Commonwealth University.

Ms. Heather L. Knight, Independent Director. Career Highlights: Solventum Corporation - Chief Commercial Officer (November 2025 - present); Baxter International - Chief Operating Officer (February 2025 - present), EVP and Group President, Medical Products & Therapies (2023 - present), President, Acute Therapies, Clinical Nutrition, Medication Delivery, Latin America and Canada (2021 - 2023), General Manager, U.S. Hospital Products (2019 - 2021); Medtronic plc - VP, General Manager (2016 - 2019). Former (past 5 Years): Titan Medical Inc. (NASDAQ: TMDI) (2021 - 2023). Education: BS, University of Buffalo.

Mr. Wei Jiang, Independent Director. Career Highlights: Bayer AG - EVP, President of Pharmaceuticals Region China and Asia Pacific (2015 - 2021), and President of Bayer Group Greater China Region (2019 - 2021); AstraZeneca plc - SVP, GRA BU & Key Accounts (2011 - 2012), other senior management roles (2006 - 2010); Guidant Corporation - Managing Director, China Operations (2004 - 2006); Eli Lilly & Company - Various management roles (1999 - 2004). Other Public Company Boards: STAAR Surgical Company (NASDAQ: STAA). Education: BBA, Campbell University; MA, Economics and Finance, Indiana State University.

Tina Wu, the Company's Senior Vice President, Waters Materials Sciences Division and President, China, assumed the role of Senior Vice President, Waters Analytical Sciences Division. Ms. Wu has more than two decades of global experience leading business-to-business organizations spanning research and development, commercial operations and manufacturing. Prior to joining the Company in June 2026, Ms. Wu was employed at DuPont (NYSE: DD) for over 20 years, where she held a series of senior leadership positions running businesses ranging from approximately $1 billion to $2.3 billion in annual net sales, most recently as Global Vice President, President of DuPont Mobility & Materials since 2021.

Dr. Claire M. Fraser, PhD, has been appointed as Director effective February 9, 2026. Fraser is a globally acclaimed genome scientist, with three decades of experience managing large research institutes. Most recently, she served as Director of The Institute for Genome Sciences, which she founded in 2007, at the University of Maryland School of Medicine, where she also served as a Professor of Medicine and Microbiology and Immunology. Dr. Fraser received a B.S. in Biology from Rensselaer Polytechnic Institute in Troy, NY, and a Ph.D. in Pharmacology from the State University of New York at Buffalo.